Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus

Neha Yadav, Gordon Morris, S. E. Harding, Shirley Ang, Gary G. Adams

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Diabetes mellitus (diabetes) is suffered by more than 180 million people and is responsible for approximately 2.9 million deaths each year. This mortality rate is expected to increase by 50 % in the next decade. Due to the inconvenience of the traditional treatment of diabetes by subcutaneous administration of insulin injection, various attempts are made in the production, purification, formulation and methods of delivery of insulin. However, despite advances in recent years, these attempts have met with limited success. Various alternative routes such as rectal, ocular, nasal, pulmonary and oral have been exploited. The pulmonary route offers great potential for the delivery of polypeptide drugs due to the large surface area for insulin absorption in the respiratory tract. But due to its low bioavailability, oral route is intensely investigated for the insulin delivery. Microencapsulation, as one of the delivery systems utilising oral route, has shown some potential progress in insulin delivery; though it is at an early stage yet it has proved to be quite encouraging providing new less toxic immunosuppressive agents. Microencapsulation may prove to be an attractive delivery system for controlled release of insulin and beneficial for therapeutic, bio-efficient and bio-effective drug delivery. In this review we discuss the possible alternative routes for insulin delivery (ocular, nasal, pulmonary and oral) and advantages and disadvantages of each. Furthermore we consider the different drug delivery strategies available (aerosols, dry powder inhalers, synthetic beta cells, hydrogels and microcapsules) and their current and potential applications with respect to the different insulin delivery routes.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume9
Issue number1
DOIs
Publication statusPublished - Mar 2009
Externally publishedYes

Fingerprint

Diabetes Mellitus
Insulin
Drug Compounding
Therapeutics
Nose
Lung
Pharmaceutical Preparations
Dry Powder Inhalers
Artificial Cells
Hydrogels
Poisons
Immunosuppressive Agents
Aerosols
Biological Availability
Capsules
Peptides
Injections
Mortality

Cite this

Yadav, Neha ; Morris, Gordon ; Harding, S. E. ; Ang, Shirley ; Adams, Gary G. / Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus. In: Endocrine, Metabolic and Immune Disorders - Drug Targets. 2009 ; Vol. 9, No. 1. pp. 1-13.
@article{591b1823d6ea42cc8ed7c9c235d9bfde,
title = "Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus",
abstract = "Diabetes mellitus (diabetes) is suffered by more than 180 million people and is responsible for approximately 2.9 million deaths each year. This mortality rate is expected to increase by 50 {\%} in the next decade. Due to the inconvenience of the traditional treatment of diabetes by subcutaneous administration of insulin injection, various attempts are made in the production, purification, formulation and methods of delivery of insulin. However, despite advances in recent years, these attempts have met with limited success. Various alternative routes such as rectal, ocular, nasal, pulmonary and oral have been exploited. The pulmonary route offers great potential for the delivery of polypeptide drugs due to the large surface area for insulin absorption in the respiratory tract. But due to its low bioavailability, oral route is intensely investigated for the insulin delivery. Microencapsulation, as one of the delivery systems utilising oral route, has shown some potential progress in insulin delivery; though it is at an early stage yet it has proved to be quite encouraging providing new less toxic immunosuppressive agents. Microencapsulation may prove to be an attractive delivery system for controlled release of insulin and beneficial for therapeutic, bio-efficient and bio-effective drug delivery. In this review we discuss the possible alternative routes for insulin delivery (ocular, nasal, pulmonary and oral) and advantages and disadvantages of each. Furthermore we consider the different drug delivery strategies available (aerosols, dry powder inhalers, synthetic beta cells, hydrogels and microcapsules) and their current and potential applications with respect to the different insulin delivery routes.",
keywords = "Aerosols, Dry powder inhalers, Hydrogels, Insulin delivery, Microcapsules",
author = "Neha Yadav and Gordon Morris and Harding, {S. E.} and Shirley Ang and Adams, {Gary G.}",
year = "2009",
month = "3",
doi = "10.2174/187153009787582405",
language = "English",
volume = "9",
pages = "1--13",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus. / Yadav, Neha; Morris, Gordon; Harding, S. E.; Ang, Shirley; Adams, Gary G.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 9, No. 1, 03.2009, p. 1-13.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus

AU - Yadav, Neha

AU - Morris, Gordon

AU - Harding, S. E.

AU - Ang, Shirley

AU - Adams, Gary G.

PY - 2009/3

Y1 - 2009/3

N2 - Diabetes mellitus (diabetes) is suffered by more than 180 million people and is responsible for approximately 2.9 million deaths each year. This mortality rate is expected to increase by 50 % in the next decade. Due to the inconvenience of the traditional treatment of diabetes by subcutaneous administration of insulin injection, various attempts are made in the production, purification, formulation and methods of delivery of insulin. However, despite advances in recent years, these attempts have met with limited success. Various alternative routes such as rectal, ocular, nasal, pulmonary and oral have been exploited. The pulmonary route offers great potential for the delivery of polypeptide drugs due to the large surface area for insulin absorption in the respiratory tract. But due to its low bioavailability, oral route is intensely investigated for the insulin delivery. Microencapsulation, as one of the delivery systems utilising oral route, has shown some potential progress in insulin delivery; though it is at an early stage yet it has proved to be quite encouraging providing new less toxic immunosuppressive agents. Microencapsulation may prove to be an attractive delivery system for controlled release of insulin and beneficial for therapeutic, bio-efficient and bio-effective drug delivery. In this review we discuss the possible alternative routes for insulin delivery (ocular, nasal, pulmonary and oral) and advantages and disadvantages of each. Furthermore we consider the different drug delivery strategies available (aerosols, dry powder inhalers, synthetic beta cells, hydrogels and microcapsules) and their current and potential applications with respect to the different insulin delivery routes.

AB - Diabetes mellitus (diabetes) is suffered by more than 180 million people and is responsible for approximately 2.9 million deaths each year. This mortality rate is expected to increase by 50 % in the next decade. Due to the inconvenience of the traditional treatment of diabetes by subcutaneous administration of insulin injection, various attempts are made in the production, purification, formulation and methods of delivery of insulin. However, despite advances in recent years, these attempts have met with limited success. Various alternative routes such as rectal, ocular, nasal, pulmonary and oral have been exploited. The pulmonary route offers great potential for the delivery of polypeptide drugs due to the large surface area for insulin absorption in the respiratory tract. But due to its low bioavailability, oral route is intensely investigated for the insulin delivery. Microencapsulation, as one of the delivery systems utilising oral route, has shown some potential progress in insulin delivery; though it is at an early stage yet it has proved to be quite encouraging providing new less toxic immunosuppressive agents. Microencapsulation may prove to be an attractive delivery system for controlled release of insulin and beneficial for therapeutic, bio-efficient and bio-effective drug delivery. In this review we discuss the possible alternative routes for insulin delivery (ocular, nasal, pulmonary and oral) and advantages and disadvantages of each. Furthermore we consider the different drug delivery strategies available (aerosols, dry powder inhalers, synthetic beta cells, hydrogels and microcapsules) and their current and potential applications with respect to the different insulin delivery routes.

KW - Aerosols

KW - Dry powder inhalers

KW - Hydrogels

KW - Insulin delivery

KW - Microcapsules

UR - http://www.scopus.com/inward/record.url?scp=65549166428&partnerID=8YFLogxK

UR - https://benthamscience.com/journals/endocrine-metabolic-and-immune-disorders-drug-targets/#top

U2 - 10.2174/187153009787582405

DO - 10.2174/187153009787582405

M3 - Review article

VL - 9

SP - 1

EP - 13

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 1

ER -